Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$23.31
+0.6%
$30.44
$22.27
$59.61
$1.13B1.38678,292 shs133,665 shs
Haemonetics Co. stock logo
HAE
Haemonetics
$85.00
-0.1%
$79.41
$70.74
$95.26
$4.32B0.36446,586 shs56,367 shs
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$74.18
$74.86
$62.58
$85.62
$4.31B0.89490,818 shs61,989 shs
NuVasive, Inc. stock logo
NUVA
NuVasive
$39.75
$39.64
$35.17
$49.53
$2.08B1.071.16 million shsN/A
Nevro Corp. stock logo
NVRO
Nevro
$12.78
-0.1%
$14.25
$11.98
$34.86
$468.77M0.89471,821 shs160,990 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+2.03%+0.30%-18.62%-31.00%-44.02%
Haemonetics Co. stock logo
HAE
Haemonetics
+1.75%+1.02%+5.97%+4.05%+0.32%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
+1.27%+1.97%+2.59%-7.14%-6.10%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.00%0.00%0.00%0.00%-7.73%
Nevro Corp. stock logo
NVRO
Nevro
+4.27%+0.95%-5.53%-29.89%-62.20%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
1.7225 of 5 stars
3.51.00.00.01.82.50.6
Haemonetics Co. stock logo
HAE
Haemonetics
4.4145 of 5 stars
2.34.00.04.33.31.72.5
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
4.8151 of 5 stars
3.44.00.03.82.82.52.5
NuVasive, Inc. stock logo
NUVA
NuVasive
1.9732 of 5 stars
3.30.00.00.00.00.03.1
Nevro Corp. stock logo
NVRO
Nevro
1.6689 of 5 stars
4.01.00.00.01.01.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$52.63125.76% Upside
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6723.14% Upside
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
2.89
Moderate Buy$92.5024.70% Upside
NuVasive, Inc. stock logo
NUVA
NuVasive
2.50
Moderate Buy$51.3329.14% Upside
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$21.2366.12% Upside

Current Analyst Ratings

Latest NUVA, ATRC, NVRO, MMSI, and HAE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$32.00
4/16/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$98.00
4/15/2024
Nevro Corp. stock logo
NVRO
Nevro
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00
4/12/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/11/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$88.00
4/11/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$88.00
4/11/2024
Nevro Corp. stock logo
NVRO
Nevro
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $16.00
4/10/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00
4/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00
4/3/2024
Nevro Corp. stock logo
NVRO
Nevro
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00
2/29/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$82.00 ➝ $87.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$399.24M2.82N/AN/A$9.84 per share2.37
Haemonetics Co. stock logo
HAE
Haemonetics
$1.17B3.69$5.06 per share16.81$16.22 per share5.24
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$1.26B3.43$4.89 per share15.18$20.81 per share3.56
NuVasive, Inc. stock logo
NUVA
NuVasive
$1.23B1.70$4.96 per share8.01$17.02 per share2.34
Nevro Corp. stock logo
NVRO
Nevro
$425.17M1.10N/AN/A$8.10 per share1.58

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.66N/AN/AN/A-7.62%-7.55%-5.83%5/1/2024 (Confirmed)
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4634.5520.051.979.97%22.37%9.71%5/9/2024 (Confirmed)
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$94.41M$1.6245.7920.272.047.51%14.63%9.19%4/30/2024 (Confirmed)
NuVasive, Inc. stock logo
NUVA
NuVasive
$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/A
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%5/7/2024 (Confirmed)

Latest NUVA, ATRC, NVRO, MMSI, and HAE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
5/7/2024N/A
Nevro Corp. stock logo
NVRO
Nevro
-$1.02N/A+$1.02N/AN/AN/A  
5/1/2024N/A
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.20N/A+$0.20N/AN/AN/A  
4/30/2024N/A
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$0.70N/A-$0.70N/AN/AN/A  
2/28/2024Q4 2023
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$0.77$0.81+$0.04$1.15$320.66 million$324.52 million    
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
N/AN/AN/AN/AN/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.15
3.57
2.66
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
0.68
5.45
3.95
NuVasive, Inc. stock logo
NUVA
NuVasive
0.50
1.25
0.65
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
99.66%
NuVasive, Inc. stock logo
NUVA
NuVasive
N/A
Nevro Corp. stock logo
NVRO
Nevro
95.52%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
3.70%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.53%
Nevro Corp. stock logo
NVRO
Nevro
3.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20048.38 million46.83 millionOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
6,95058.07 million55.92 millionOptionable
NuVasive, Inc. stock logo
NUVA
NuVasive
3,00052.45 million52.17 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.51 millionOptionable

NUVA, ATRC, NVRO, MMSI, and HAE Headlines

SourceHeadline
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
finance.yahoo.com - April 17 at 10:38 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
prnewswire.com - April 17 at 8:30 AM
Nevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of CanadaNevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of Canada
americanbankingnews.com - April 16 at 3:44 AM
Nevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of CanadaNevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of Canada
marketbeat.com - April 15 at 3:31 PM
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by Analysts
marketbeat.com - April 12 at 2:33 AM
Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00
marketbeat.com - April 11 at 8:25 AM
Nevro (NYSE:NVRO) Trading Up 5.5%Nevro (NYSE:NVRO) Trading Up 5.5%
marketbeat.com - April 9 at 12:12 PM
Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)
marketbeat.com - April 5 at 4:35 AM
Where Nevro Stands With AnalystsWhere Nevro Stands With Analysts
benzinga.com - April 3 at 1:52 PM
Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00
marketbeat.com - April 3 at 12:14 PM
Nevro (NYSE:NVRO) Stock Price Down 4.8%Nevro (NYSE:NVRO) Stock Price Down 4.8%
marketbeat.com - April 1 at 2:58 PM
EnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization
finanznachrichten.de - March 25 at 4:30 PM
Heres Why You Should Retain Nevro (NVRO) Stock for NowHere's Why You Should Retain Nevro (NVRO) Stock for Now
zacks.com - March 21 at 1:36 PM
NVRO Mar 2024 20.000 putNVRO Mar 2024 20.000 put
finance.yahoo.com - March 11 at 12:27 AM
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral ScrewNevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
zacks.com - February 29 at 8:31 AM
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
prnewswire.com - February 28 at 4:10 PM
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
markets.businessinsider.com - February 27 at 1:07 AM
Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty
markets.businessinsider.com - February 26 at 7:38 AM
Nevro just downgraded at Oppenheimer, heres whyNevro just downgraded at Oppenheimer, here's why
realmoney.thestreet.com - February 23 at 2:42 AM
Nevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - February 22 at 9:41 PM
Why Nevro Stock Lagged the Market on ThursdayWhy Nevro Stock Lagged the Market on Thursday
fool.com - February 22 at 6:21 PM
Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 OutlookHold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook
markets.businessinsider.com - February 22 at 2:16 PM
Analyst Scoreboard: 4 Ratings For NevroAnalyst Scoreboard: 4 Ratings For Nevro
markets.businessinsider.com - February 22 at 2:16 PM
Nevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call TranscriptNevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 22 at 2:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Merit Medical Systems logo

Merit Medical Systems

NASDAQ:MMSI
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
NuVasive logo

NuVasive

NASDAQ:NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.